Zacks.com on MSN6d
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin UpCTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...
Catalent (NYSE:CTLT – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report ...
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...
Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...
Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.
On Friday, Catalent Inc (CTLT) stock saw a decline, ending the day at $59.41 which represents a decrease of $-0.51 or -0.85% from the prior close of $59.92. The stock opened at $59.81 and touched a ...
Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Catalent (CTLT – Research Report), Moderna (MRNA – Research ...
The advocacy groups said at the time that the deal could constrain competitors such as Amgen, Pfizer, Roche and AstraZeneca, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback